Literature DB >> 31373864

The clinical and economic burden of varicella in the Middle East: a systematic literature review.

Nawal Al Kaabi1, Fatma Mohd Ali Sultan Al Olama2, Mamoun Al Qaseer3, Idris Al Ubaidani4, Ener Cagri Dinleyici5, Wail Ahmad Hayajneh6, Abdul Rahman Bizri7, Maysoon Loulou8, Tidiane Ndao9, Lara J Wolfson10.   

Abstract

This systematic literature review was conducted to better understand the epidemiology and burden of varicella across the Middle East, gain insight into the evidence to support using universal varicella vaccination (UVV), and identify potential data gaps. Both epidemiology and economic data on the burden of varicella were limited and varied significantly. Most of the data focussed on varicella burden in the absence of a UVV program. In the absence of UVV, varicella incidence is increasing across this region with varicella infection associated with substantial morbidity. Although limited, data on the impact of vaccination at a population level indicated UVV programs reduce varicella incidence and hospitalizations, in line with global experience. Further research and action are needed to better understand varicella epidemiology in the Middle East, increase awareness and understanding in the region, and provide local data to support national public-health decisions regarding the implementation of UVV programs.

Entities:  

Keywords:  Middle East; seroprevalence; systematic literature review; vaccination; varicella

Mesh:

Year:  2019        PMID: 31373864      PMCID: PMC7012098          DOI: 10.1080/21645515.2019.1638726

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  60 in total

1.  Immunity to chickenpox among school adolescents in Lebanon and options for vaccination.

Authors:  U M Musharrafieh; I A Nuwayhid; G N Hamadeh; S W Steitieh; A R N Bizri
Journal:  Epidemiol Infect       Date:  2002-12       Impact factor: 2.451

2.  Herpes simplex virus type 1 (HSV-1) and varicella-zoster virus (VZV) infections in Saudi Arabia.

Authors:  A Hossain
Journal:  J Trop Pediatr       Date:  1989-08       Impact factor: 1.165

3.  Assessment of sociodemographic factors and socio-economic status affecting the coverage of compulsory and private immunization services in Istanbul, Turkey.

Authors:  A Topuzoglu; G A N Ozaydin; S Cali; D Cebeci; S Kalaca; H Harmanci
Journal:  Public Health       Date:  2005-10       Impact factor: 2.427

4.  The effectiveness of varicella vaccination during an outbreak in a children's day-care center.

Authors:  Ayşe Kiliç; Emin Unüvar; Ceren Yilmaz; Ismail Yildiz; Fatma Oğuz; Mujgan Sidal
Journal:  Vaccine       Date:  2008-04-30       Impact factor: 3.641

5.  Bacterial complications of primary varicella in children.

Authors:  C Aebi; A Ahmed; O Ramilo
Journal:  Clin Infect Dis       Date:  1996-10       Impact factor: 9.079

6.  Cost-effectiveness of Varicella Vaccination Program in Iran.

Authors:  Shooka Esmaeeli; Mohsen Yaghoubi; Marzieh Nojomi
Journal:  Int J Prev Med       Date:  2017-12-05

7.  Economic burden of varicella in children 1-12 Years of age in Hungary, 2011-2015.

Authors:  Z Meszner; Z Molnar; E Rampakakis; H K Yang; B J Kuter; Lara J Wolfson
Journal:  BMC Infect Dis       Date:  2017-07-14       Impact factor: 3.090

Review 8.  Varicella infection in the Middle East: Prevalence, complications, and vaccination.

Authors:  Mariam Al-Turab; Wassim Chehadeh
Journal:  J Res Med Sci       Date:  2018-04-26       Impact factor: 1.852

9.  Clinical epidemiology of chickenpox in Iraq from 2007-2011.

Authors:  Hanan Abdulghafoor Khaleel; Hassan Muslem Abdelhussein
Journal:  Glob J Health Sci       Date:  2012-11-21

10.  Seroprotection against Vaccine-Preventable Diseases amongst Health Care Workers in a Community Hospital, Qatar.

Authors:  H Guanche Garcell; A Villanueva Arias; E Guilarte García; R N Alfonso Serrano
Journal:  Int J Occup Environ Med       Date:  2016-10
View more
  1 in total

1.  Acceptance of varicella vaccination.

Authors:  Andrea Horváth
Journal:  Hum Vaccin Immunother       Date:  2020-12-16       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.